Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Pediatric Cardiology and Congenital Heart Defect Division, Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
Curr Cardiol Rev. 2022;18(1):e030621193817. doi: 10.2174/1573403X17666210603113430.
Junctional Ectopic Tachycardia (JET) is an arrhythmia originating from the AV junction, which may occur following congenital heart surgery, especially when the intervention is near the atrioventricular junction.
The aim of this systematic review and meta-analysis is to compare the effectiveness of amiodarone, dexmedetomidine, and magnesium in preventing JET following congenital heart surgery.
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement, where 11 electronic databases were searched from the date of inception to August 2020. The incidence of JET was calculated with the relative risk of 95% Confidence Interval (CI). Quality assessment of the included studies was assessed using the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement.
Eleven studies met the predetermined inclusion criteria and were included in this meta-analysis. Amiodarone, dexmedetomidine, and magnesium significantly reduced the incidence of postoperative JET [Amiodarone: risk ratio 0.34; I2= 0%; Z=3.66 (P=0.0002); 95% CI 0.19-0.60. Dexmedetomidine: risk ratio 0.34; I2= 0%; Z=4.77 (P<0.00001); 95% CI 0.21-0.52. Magnesium: risk ratio 0.50; I2= 24%; Z=5.08 (P<0.00001); 95% CI 0.39-0.66].
All three drugs have shown promising results in reducing the incidence of JET. Our systematic review found that dexmedetomidine is better in reducing the length of ICU stays as well as mortality. In addition, dexmedetomidine also has the least pronounced side effects among the three. However, it should be noted that this conclusion was derived from studies with small sample sizes. Therefore, dexmedetomidine may be considered as the drug of choice for preventing JET.
交界性心动过速(JET)是一种起源于房室结的心律失常,可能发生在先天性心脏手术后,特别是当干预靠近房室结时。
本系统评价和荟萃分析的目的是比较胺碘酮、右美托咪定和镁在预防先天性心脏手术后 JET 中的效果。
根据系统评价和荟萃分析的首选报告项目(PRISMA)声明,本荟萃分析检索了从成立日期到 2020 年 8 月的 11 个电子数据库。JET 的发生率用 95%置信区间(CI)的相对风险计算。采用 CONSORT 2010 声明评估纳入研究的质量。
11 项研究符合预定的纳入标准,并纳入本荟萃分析。胺碘酮、右美托咪定和镁可显著降低术后 JET 的发生率[胺碘酮:风险比 0.34;I²=0%;Z=3.66(P=0.0002);95%CI 0.19-0.60.右美托咪定:风险比 0.34;I²=0%;Z=4.77(P<0.00001);95%CI 0.21-0.52.镁:风险比 0.50;I²=24%;Z=5.08(P<0.00001);95%CI 0.39-0.66]。
这三种药物均显示出降低 JET 发生率的良好效果。我们的系统评价发现,右美托咪定在降低 ICU 住院时间和死亡率方面效果更好。此外,右美托咪定在这三种药物中的副作用最小。然而,应该注意的是,这一结论是基于样本量较小的研究得出的。因此,右美托咪定可能被认为是预防 JET 的首选药物。